Clinical Trial Update: Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating continuous daily dosing of SU011248 in patients with gastrointestinal stromal tumors has completed, with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• SU011248

Snippet

Sponsor: Pfizer | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED | Results posted: 2009-09-04